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El Cant del Barça 
Tot el camp 
és un clam 
som la gent blaugrana 
Tant se val d'on venim 
si del sud o del nord 
ara estem d'acord,estem d'acord,  
una bandera ens agermana. 
Blaugrana al vent 
un crit valent 
tenim un nom el sap tothom: 
Barça, Barça, Barça! 
Jugadors, seguidors, 
tots units fem força. 
Són molt anys plens d'afanys, 
són molts gols que hem cridat 
i s'ha demostrat, s'ha demostrat, 
que mai ningú no ens podrà torcer. 
Blaugrana al vent 
un crit valent 
tenim un nom el sap tothom: 
Barça, Barça, Barça! 
ABSTRACT 
Kidney glomeruli function as high-capacity molecular sieves through which 
plasma is filtered into the Bowman’s space as primary urine. The glomerular filtration 
barrier is composed of glomerular endothelial cells, the glomerulus basement 
membrane and the podocyte cell layer. Dysfunction of the glomerulus is a central 
component of renal complications leading to end-stage renal disease. However, the 
molecular composition of the glomerulus and how it changes during disease are still 
mostly unknown. To elucidate the picture of molecules involved in the biology and 
pathology of the glomerulus, large-scale approaches including two-dimensional gel 
electrophoresis (2-DE) coupled with mass spectrometry analysis and microarray 
profiling were applied to normal and diseased glomeruli.  
A proteome analysis of healthy glomeruli in mouse was performed using 2-DE 
with two different staining methods and subsequent mass spectrometric 
identifications. Altogether, 414 protein spots were identified, revealing 232 different 
proteins representing a wide spectrum of activities. Only 53 of the proteins identified 
here were detected in another proteome study, showing the value of analysis utilizing 
different methodologies. 80 of the proteins were not identified in a separate 
transcriptome analysis, while ten of the present proteins were identified as genes 
implicated in glomerulus development and function, allowing direct correlation with 
expression data. 
Characterization of five glomerulus-upregulated transcripts/proteins, ehd3, 
dendrin, sh2d4a, plekhh2, and 2310066E14Rik was performed. The expression pattern 
of these novel glomerular transcripts in various mouse tissues was studied, and the 
distribution of corresponding proteins was examined. All five transcripts/proteins were 
expressed in the kidney exclusively by glomerular cells. Ehd3 was expressed only by 
glomerular endothelial cells. Importantly, ehd3 is the first gene ever shown to be 
expressed exclusively by glomerular endothelial cells and not by other endothelial cells 
in the kidney. Dendrin, sh2d4a, plekhh2, and 2310066E14Rik were transcribed 
specifically in podocytes within the glomerulus. With the use of polyclonal antibodies, 
dendrin, sh2d4a, and plekhh2 proteins were localized to the slit diaphragm and the foot 
process, whereas 2310066E14Rik protein was localized to the podocyte major 
processes and cell body.  
Comparison of the normal glomerular transcriptome with its changes during 
progression of glomerular disease can yield information about molecular 
pathomechanisms. The adriamycin (ADR)-induced proteinuric mouse model allows the 
precise timing of the onset of proteinuria and of morphological changes in glomerulus. 
Overt proteinuria was observed from four days after ADR injection, and reached 
maximum at seven days. Blood urea nitrogen (BUN) gradually elevated indicating the 
failure of renal function. TUNEL staining of kidney section revealed an increase in 
apoptotic positive cells in glomeruli. Transcriptional profiling of kidney glomeruli 
revealed that nine p53 target genes were up-regulated probably due to DNA damage 
caused by ADR at four days and several glomerular enriched genes were differentially 
expressed indicating glomerular injury at seven days.  
These studies provide fresh insights into glomerular biology and reveal new 
possibilities to explore the role of glomerular specific proteins in renal physiology and 
pathophysiology. Furthermore, these studies shed light on the pathomechanisms of 
proteinuria, which eventually results in end-stage kidney disease as a result of 
progressive glomerular damage.  
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1 Introduction: Review of literature 
1.1  The kidney  
The kidneys are paired, bean-shaped organs, whose primary function is to filter 
metabolic waste products from the blood into urine. In adult humans about 180 liters of 
blood is filtered through the kidneys every day as primary urine, which is devoid of 
macromolecules that are essential for maintaining homeostasis. The primary urine is 
comprehensively modified in the renal tubular system, both in composition and 
volume, and the daily excretion is normally about 1–1.5 liters. In addition, the kidneys 
have multiple other functions such as maintenance of acid-base homeostasis, osmolality 
and blood pressure regulation, vitamin D metabolism and production of hormones like 
erythropoietin and renin. 
 
1.1.1 Glomerulus 
The glomerulus is the filtration unit of the kidney. It is a capillary tuft surrounded 
by the Bowman’s capsule at the proximal end of the nephron. Each adult human kidney 
contains about a million glomeruli, which are located in the cortex. The glomerulus 
contains four resident cell types: parietal epithelial cells (PECs) of the Bowman’s 
capsule, whilst mesangial cells, endothelial cells, and podocytes are within the 
glomerular tuft [1-2]. Figure 1 illustrates the anatomical details of kidney glomerulus. 
 
 
Figure 1. Schematic picture of the kidney glomerulus 
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The glomerular filtration barrier is composed of three layers: the fenestrated 
glomerular endothelial cells (GECs), the glomerular basement membrane (GBM) and 
the slit diaphragm (SD) located between the interdigitating podocyte foot processes 
(Figure 2). Plentiful evidence from biochemical and physiological analysis of the 
glomerular filter barrier has emerged, suggesting that the glomerular filter barrier 
functions in a size- and charge-selective manner [3-4], but its literal character and 
intricate properties have been and still are a matter of debate [5]. 
 
 
 
Figure 2. The glomerular filtration barrier  
The filtration barrier of the capillary wall contains the innermost fenestrated endothelium, the glomerular 
basement membrane (GBM) and the podocyte. The slit diaphragm (SD) is located between the foot 
processes. The arrow indicates the direction of flow of primary urine.  
 
1.1.2 Podocytes and slit diaphragm  
Podocytes, also called glomerular visceral epithelial cells, are located on the outer 
surface of the GBM and contribute the outermost layer of the glomerular filtration 
barrier. They are highly polarized cells with an extremely unique trait; the mature 
podocytes are post-mitotic cells, which cannot proliferate since they arrest in the G2/M 
phase of the cell cycle [6]. With regards to their cytoarchitecture, the podocyte can be 
morphologically segregated into three different portions; cell body, major processes 
and foot processes. A capacious cell body, which lumps into the urinary space, 
possesses a well-developed endoplasmic reticulum, a large Golgi apparatus, and 
abundant mitochondria and lysosomes. This indicates that they have a high capacity for 
protein synthesis and post-translational modifications to maintain the dynamic and 
complex structure and function of the slit diaphragm [7]. The cell body induces long 
primary processes, which divide into secondary processes and eventually form the foot 
processes [8]. Interdigitated foot processes of adjacent podocytes leave narrow slits 
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between them, and those slits are bridged by a well-organized extracellular structure 
with a constant width of 30-45 nm [7, 9]. This specialized intercellular junction is 
known as the slit diaphragm (SD). 
Previously, the structure of the SD was proposed to be a zipper‐like membrane 
with pores smaller than the size of albumin molecules on both sides of a central 
filament [9-10]. Recently, new information on the structure of the SD has been revealed 
by electron tomography combined with immunogold‐labeling that the SD may be 
composed of a uniformly organized network of convoluted strands [11]. Furthermore, 
accumulating evidence on protein complexes specifically located in the SD has 
supported the notion of the SD as being a genuine macromolecular barrier. CD2AP 
[12], nephrin [13], Neph1 [14] and podocin [15] have been found to be specifically 
localized to the SD region, and abnormal function or absence of any of these proteins 
leads to proteinuria and progression to renal failure in humans or mice. Thus, the 
podocytes and the SD are considered to have a central role in glomerular filtration.  
 
1.1.3 Glomerular endothelial cells and glomerular basement 
membrane 
The glomerular endothelial cells (GECs) form the innermost layer of the 
glomerular capillary wall with a large fenestrated area representing 20–50% of the 
entire endothelial surface [16]. The diameter of the fenestrae is about 60 nm [17]. Thus, 
GECs do not seem to be a direct barrier for the passage of plasma proteins in a size-
selective manner [18-19]. It is possible that the GECs contribute to the physical 
glomerular filtration barrier, but detailed knowledge about its function remains unclear. 
The glomerular basement membrane (GBM) is a 300 nm thick acellular matrix 
membrane located between GECs and podocytes [20]. Its main constituents are type IV 
collagen, laminin, nidogen and proteoglycans. Collagens and laminins form a huge 
structural network by self assembly, and nidogen is believed to be the connector of 
these networks in the GBM [21]. The most abundant proteoglycans in the GBM are 
heparan sulphate proteoglycans (HSPGs), such as agrin and perlecan [22-23]. They 
contribute to the negative charge of the GBM [24]. This trait of the GBM has been 
considered to play an important role in preventing negatively-charged plasma proteins 
from passing through the glomerular filtration barrier [25]. However, the role of 
HSPGs in glomerular filtration has been interrogated as genetically modified HSPGs 
deficient mice do not develop proteinuria [26-28]. 
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1.2   Proteinuria and nephrotic syndrome 
Nephrotic syndrome (NS) is not a disease itself, but the symptom of many 
different proteinuric diseases of the kidney glomerulus, which can be acute and 
transient or chronic and progressive. NS is an exceedingly heterogeneous disorder, 
which is triggered either by acquired or by genetic defects in the glomerular filtration 
barrier. NS is characterized by the triad of overt proteinuria, hypoalbuminemia, and 
edema, and often the conditions related to NS eventually result in end-stage kidney 
failure as a result of progressive glomerular damage [29]. Proteinuria is characterized 
by the presence of excess plasma proteins in the urine, and it is one of the most 
prominent indications of glomerular filtration barrier dysfunction. When protein 
excretion exceeds 3.5 g or more per day, it is considered as nephrotic-range proteinuria 
in human adults [30]. The pathogenic mechanisms of proteinuria have been clarified in 
some rare inherited diseases, but the causes of most human proteinuria cases are still 
unclear. Elucidation of the pathomechanisms and specific treatments for these diseases 
are the most important premises in the nephrology field. Recent discovery and 
identification of genes causing NS and consequent research on the function of the 
proteins encoded by these genes have increased the current understanding of NS [31].  
 
1.2.1 Acquired proteinuria syndromes in humans 
The majority of proteinuria syndromes in humans are acquired, and these are 
divided into immune and non-immune mediated [32]. The most common immune-
mediated forms are membranous nephropathy (MN) and minimal change disease.  MN 
is the most common cause of NS in adults. The traits that characterize MN as a 
histopathological entity are caused by the immune deposits that form at the base of the 
foot processes of podocyte. The name membranous originated from the thickened 
GBM that is often observed by light microscopy in later stages of the disease. The 
immune deposits and the additional matrix material laid down by the injured podocytes 
are responsible for thickening of the GBM as the disease progresses [33]. The target 
antigen podocyte foot processes in patients with MN has been under intense research 
for decades. Very recently, Beck et al. identified protein termed M-type phospholipase 
A2 receptor (PLA2R) as the target antigen in idiopathic membranous nephropathy [34].  
PLA2R is expressed on normal glomerular podocytes and is present in the glomerular 
immune deposits in patients with the disease. Their discovery is a major breakthrough 
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and may have implications for the diagnosis and treatment of the idiopathic 
membranous nephropathy. 
Minimal change disease is considered immune-mediated because it is likely in 
consequence of an abnormality in T cells, although the precise mechanisms are not well 
defined [32]. It is by far the most common cause of NS in children under 10 years of 
age [35]. The name minimal change disease derived from no morphrogical changes in 
kidney observed under light microscopy. However, the hallmarks for this disease, 
podocyte foot processes effacement, vacuolation, and growth of microvilli on podocyte 
were observed with the advent of electron microscopy.  
The most common non-immune mediated proteinuria syndrome is diabetic 
nephropathy (DN). DN, characterized by initial development of progressive 
albuminuria followed by a later decline in glomerular filtration in association with 
glomerulosclerosis, is the most common cause of end-stage renal disease [36], and it is 
also an independent risk factor for cardiovascular disease [37]. Renal extracellular-
matrix accumulation and thickening of the GBM and the tubular basement membrane 
are distinctive traits of DN pathology. It is suggested that inheritance plays an 
important role in the pathogenesis of DN based on a high concordance rate for DN in 
families, and different rates of DN in disparate racial groups [38-39]. The search for 
identification of genetic variants underlying heritable risk of DN by either genome-
wide scans or candidate-gene approaches has been conducted for a long time. Several 
studies have reported that the 3q locus is likely to harbor susceptibility gene(s) for DN 
[40-41]. Recently, He et al. reported the association of genetic variants at 3q22 with an 
increased risk of DN by genotyping highly dense single-nucleotide polymorphisms 
[42]. Despite intensive research efforts actual DN causative genes have not been 
identified yet. 
 
1.2.2 Inherited proteinuria syndromes in humans 
The inherited forms of proteinuria in humans have diverse courses. Some have 
moderate proteinuria and focal segmental glomerulosclerosis (FSGS), while others have 
rigorous proteinuria or congenital nephrotic syndrome. Regardless of the causes for 
those symptoms, the patients often end up with end-stage renal disease, which requires 
hemodialysis treatment or a kidney transplantation [31]. Furthermore, the trait of these 
hereditary proteinuria syndromes can be sorted in a clearly age-dependent manner. 
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Steroid-resistant nephrotic syndrome is an autosomal recessive inherited 
disorder, which is characterized by early childhood onset of proteinuria, rapid 
progression to end-stage renal disease and focal segmental glomerulosclerosis [15]. 
This disease is caused by mutations in NPHS2 gene in about 25% of children and 
nearly 15% of adults [43]. NPHS2 encodes a protein termed podocin [44-45]. Podocin, 
a 42-kDa hairpin-like protein, is localized at the slit diaphragm. It is a raft-associated 
component of the slit diaphragm and interacts directly with nephrin and CD2AP [46]. 
Mutations in podocin disrupt the slit diaphragm as it may serve a scaffolding function 
and serves in the structural organization of the slit diaphragm [47]. 
Congenital nephrotic syndrome of the Finnish type (CNF) is also an autosomal 
recessive inherited disorder, which is characterized by massive proteinuria already in 
utero, premature birth and edema just after the birth [48]. The incidence of this disease 
in Finland is 1 in 8,200 births [49], but has been diagnosed worldwide. CNF is caused 
by the mutations in NPHS1, which encodes a protein termed nephrin [13, 50]. 
Nephrin, a 180 kDa transmembrane protein, is localized at the podocyte SD, and 
functions as structural component that maintains and organizes podocyte cytoskeleton 
[51]. Mutations in the NPHS1 gene hinder the formation of the slit diaphragm and lead 
to massive proteinuria and renal failure. 
Hereditary forms of focal segmental glomerulosclerosis (FSGS) are often 
characterized by the onset of mild proteinuria during adolescence or early adulthood, 
with slow progression to segmental glomerulosclerosis [31]. Mutations in two genes 
have been identified as responsible for two types of FSGS, FSGS1 and FSGS2.  FSGS1 
is caused by mutations in ACTN4, which encodes α-actinin-4 [52]. α-actinin-4, a 105 
kDa cytosolic protein, is located in the podocyte, and it cross-links F-actin filaments in 
the foot processes. Known mutations in the ACTN4 gene increase the affinity of α-
actinin-4 for F-actin, which may interfere with the normal assembly and disassembly of 
actin filaments in the glomerular podocytes [53]. FSGS2 is caused by mutations in 
TRPC6, which encodes transient receptor potential cation channel 6 (TRPC6) [54-55]. 
TRPC6, a 106 kDa transmembrane protein, is localized to the podocyte, and it is a 
member of a family of nonselective cation channel proteins that are involved in the 
increase of intracellular calcium concentration. Mutations in the TRPC6 gene cause 
abnormally high current amplitudes, which may have a role in the pathogenesis of focal 
segmental glomerulosclerosis [56]. Mutations in a few other podocyte genes have been 
reported to cause progressive proteinuria. Table 1 summarizes some of these genes. 
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Table 1. Summary of genetic form of nephrotic syndrome 
Disease  Gene Protein Protein location Ref(s) 
Steroid-resistant NS NPHS2 Podocin Podocyte [44-45] 
Congenital NS of Finnish type NPHS1 Nephrin  Podocyte SD* [48, 57] 
Focal segmental glomerulosclerosis 1 ACTN4 α-Actinin 4 Podocyte [52] 
Focal segmental glomerulosclerosis 2 TRPC6 Transient receptor potential cation channel C6 Podocyte [54-55] 
Denys–Drash syndrome WT1 WT1 protein Podocyte [58-60] 
Pierson syndrome LAMB2 Laminin β2 GBM** [61] 
* Slit diaphragm  ** Glomerular basement membrane     
 
1.2.3 Experimental proteinuric rodent models  
Experimental proteinuric rodent models can be used to explore mechanisms of 
proteinuria induction and progression, and the development and better depiction of 
these models has advanced our understanding of human glomerular diseases. It is ideal 
to employ human sample/tissue to clarify the whole picture of proteinuric diseases, but 
there are some drawbacks with utilizing human tissue. These include limitations with 
sample collection, restriction to the time of disease onset and exceptional routines in 
follow-up [62]. On the other hand, using proteinuric rodent models overcomes these 
impediments, as they are easily accessible to sample collection and examination of 
development and progression of the disease over time. It is also desirable to control the 
onset of proteinuria or to disrupt/overexpress a particular gene that might be involved 
in the pathogenesis of proteinuria [62]. Furthermore, the use of rodent models has 
advantages such as low cost, easy handling and short reproductive periods. 
Experimental rodent proteinuric models induced by numerous nonimmunological 
procedures have been well characterized and include partial nephrectomy [63-64], 
protein overload [65] and administration of puromycin (PAN) [66],  adriamycin (ADR) 
[67-68], protamine sulphate (PS) [69-70], and lipopolysaccaride (LPS) [71-74].  Table 
2 summarizes details of these methods. 
 
Table 2. Summary of rodent experimental proteinuric models 
Models Species Human Disease Type of PU** Onset of PU Ref (s) 
protein overload  Rat/Mouse NS* Transient 6-24 hours [65] 
PAN nephrosis Rat FSGS Transient 5-8 days [66] 
ADR nephrosis Rat/Mouse FSGS Progressive 4-7 days [67-68] 
PS model Rat NS Transient 40-70 minutes [69-70] 
LPS model Mouse NS Transient 24 hours [71-74] 
* No specific human disease, ** Proteinuria  
(Modified from Pippin et al., 2009) 
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1.2.3.1 Adriamycin induced proteinuric mouse model  
Adriamycin (ADR), the trade name of Doxorubicin, is an anthracycline antibiotic 
that works by intercalating DNA. Injecting ADR intravenously to rodents induces 
proteinuria and histological features, which mimic human FSGS. Hence the ADR-
induced proteinuric model is considered an experimental form of human FSGS. This 
model has been well characterized in most rat strains since 1970 [72], however, most 
mouse strains do not show complete susceptibility to ADR. In mice, the first ADR-
induced proteinuric model was described in the BALB/c strain in 1995 [68], and Wang 
et al. established a stable and reproducible model in 2000 [67]. In 2005, Zheng et al. 
figured out that a single gene defect results in ADR susceptibility with recessive 
inheritance by mapping the trait locus to chromosome 16A1-B1 (DOXNPH locus) [75]. 
They identified the gene encoding protein arginine methyltransferase 7 (Prmt7), which 
is located in the region of the DOXNPH locus, following ADR exposure. Their theory 
is that direct methylation of ADR by Prmt7 mediates protection from kidney injury, as 
methylation of ADR has been reported to decrease its cytotoxicity aptitude [76]. Since 
then, it is known that BALB/cJ and 129/SvJ mice have severe susceptibility to ADR, 
while other mouse strains are completely resistant to ADR [77]. 
To induce ADR nephropathy, ADR is administered as a single intravenous 
injection of 10-11 mg/kg body weight. ADR nephropathy is characterized by persistent 
proteinuria, increased serum creatinine and progressive renal injury [67]. A distinctive 
benefit of using the ADR nephropathy model is that it enables specific timing of the 
onset of renal injury. In general, overt proteinuria emerges at 4-5 days after ADR 
injection. Segmental podocyte foot process fusion is observed by electron microscopy 
after a week. Apparent histological changes, including glomerular hypertrophy, 
reabsorption droplets and intratubular protein casts, are observed by light microscopy 
after two weeks. The sizes of glomeruli are reduced with glomerular vacuolization, tuft 
collapse and mesengial expansion after four weeks. FSGS and rigorous interstitial 
fibrosis and inflammation are observed after six weeks [62]. 
Even though the scientific evidence about ADR nephropathy is accumulating, the 
pathogenesis of renal damage by ADR is still not clear. Dai et al. showed that Wnt/β-
catenin signaling might be a decisive player in the pathogenesis of podocyte 
dysfunction and proteinuria in ADR nephrosis [78]. They demonstrated that up-
regulation of the Wnt1 gene in mice by ADR aggravated podocyte injury and 
albuminuria, while blockade of Wnt signaling with its antagonist DKK1 improved 
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podocyte lesions. Also, they illustrated that mice with podocyte-specific ablation of β-
catenin, the principal downstream effecter of Wnt signaling, were protected against the 
development of albuminuria by ADR. Other groups have suggested that 
phosphorylation of certain proteins, in the JAK/STAT signaling pathway [79] or in the 
MAPK pathway [80], may exacerbate experimental acute renal injury. They 
demonstrated that phosphorylation of the protein in either pathway is enhanced in 
glomeruli of clinical nephrotic syndrome and of mice with ADR nephropathy and 
inhibition of phosphorylation of those proteins results in marked suppression of renal 
injury and proteinuria. Therefore, they concluded that activation of the JAK/STAT or 
the MAPK signal pathway is involved in the progression of glomerular diseases with 
proteinuric state. 
Several groups have suggested that the alternative pathway of the complement 
cascade is vital in mediating the early podocyte injury and late onset glomerulosclerosis 
in the ADR nephropathy model. They used KO mice for various complement cascade 
components, including C3, C3 receptor, C1q, factor D, factor B or the complement 
regulatory protein CD59a [81-84], and concluded that renal injury by ADR was 
dependent on the activation of complement through C3. One group has suggested that 
activation of the complement system is implicated in the development of 
tubulointerstitial injury, which has the common pathway leading to renal failure. The 
other group has suggested that lack of component in complement cascade reduces early 
glomerular injury and proteinuria. 
 
1.2.3.2 Lipopolysaccaride induced proteinuric mouse model 
Lipopolysaccaride (LPS), a major component of the outer membrane of gram-
negative bacteria, is an endotoxin that induces a variety of inflammatory responses in 
rodents. LPS binds to the Toll-like receptor 4 (TLR-4) complex, which contains CD-14 
and MD-2, and these interactions trigger the secretion of pro-inflammatory cytokines 
[85-86]. The LPS-induced sepsis model has frequently been studied in rat [87], but 
Reiser et al. have described a transient proteinuric mouse model induced by LPS [74].  
In this model, proteinuria is induced by administering LPS as a single 
intraperitoneal injection of 200 µg of LPS diluted in PBS at a concentration of 1 mg/ml. 
Three mouse strains, BALB/c, WT 129 and C57BL/6, are known to be susceptible to 
LPS [74]. Ordinarily, a milder form of proteinuria than in the ADR-induced model 
appears within 24 hours after LPS injection, but kidney function returns to baseline by 
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72 hours. Podocyte foot process effacement is observed by electron microscopy within 
24 hours.  
Sun et al. have reported global glomerular gene expression profile changes in the 
LPS-induced proteinuric mouse model [88]. A transcriptome analysis revealed 
significant changes in mRNAs encoding proteins involved in the regulation of adherens 
junctions, actin cytoskeleton and survival in podocytes. Also, they showed significant 
downregulation of podocyte-specific genes suggesting that podocytes and the podocyte 
actin cytoskeleton were culprits in the proteinuric response to LPS. Even though 
scientific evidence about this model has been accumulating, the mechanisms of how 
LPS induces proteinuria in mice are still unknown. 
The relevance of the LPS-induced proteinuric model to human kidney disease has 
been questioned. Comper [89] has claimed that the small changes in protein excretion 
in LPS-mediated proteinuria, three-fold in proteinuria and five- to seven-fold in 
albuminuria [90], is not comparable with any human proteinuric diseases, in which 
100-10,000 fold changes in albumin excretion are observed [91]. Furthermore, he has 
claimed that the distinct effect of LPS on glomerular permeability have not been 
supported experimentally [89]. In response to Comper’s statement, Reiser and Mundel 
made an objection that this model was a significant tool to study podocyte biology and 
proteinuria, based on the facts that key effectors of this model, including B7-1 [74], 
cathepsin L [92] and urokinase-type plasminogen activator receptor [93] are induced in 
human proteinuric diseases and those proteins have been detected in podocytes in vivo 
[94].  
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1.3 Omics in the post genomic era 
The importance of determining the entire genome sequence of humans has been 
well acknowledged since the draft human genome sequence was completed ahead of 
schedule in 2001 [95-96]. Genomics provides sequence information on the full 
complement of genes in an organism, and to date, there have been more than 180 
genomes fully sequenced [97]. Therefore, genomics has facilitated the power of high-
throughput and comprehensive analysis of biological systems.  
In the post human genome era, several ''omics'' fields have emerged to facilitate 
our understanding of transcriptional regulation (transcriptomics) and the biochemical 
functions of all the gene products (proteomics). In contrast to traditional biochemical 
methods, omics techniques offer the potential to cross-examine thousands of 
independent variables in a single study, and thereby guarantee accelerated manners in 
identifying novel drug targets and in understanding the underlying mechanisms of 
health and disease [98]. 
 
1.3.1 Gene expression profiling and microarray analysis  
The central genetic doctrine utters that genomic DNA is first transcribed into 
mRNA, after which it is translated into protein. While the genome, the genes and the 
non-coding sequences of the DNA are generally common to all the cells in an 
organism and are normally static over its lifetime, the transcriptome, the collection of 
mRNA, is highly dynamic and changes in response to external stimuli and in disease 
[99]. Therefore, measuring the expression levels of mRNA provides a more accurate 
view of gene expression. 
Gene expression profiling is the term that describes the analysis of the 
transcriptome by simultaneous quantification of mRNAs levels expressed from large 
numbers of genes [99]. A wide range of technologies, both low and high throughput 
techniques, exist for the measurement of gene expression at the level of mRNA, 
including Northern blotting [100], quantitative real time RT-PCR (qRT-PCR)[101], 
real competitive PCR [102] and serial analysis of gene expression (SAGE) [103]. 
In 1995, the technique called DNA microarray was reported [104], and this 
technology has revolutionized research in gene expression analysis. Compared to 
conventional methods for gene expression measurements, which were performed at a 
gene-by-gene level, microarray technology allows simultaneous analysis of the 
expression of thousands of genes. Since the advent of this technology, microarray 
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techniques have been rapidly accepted as one of the most promising methods for gene 
expression profiling, and the application of this technique in molecular biology 
research has grown exponentially.  
By definition, a microarray is a large collection of gene specific DNA fragments 
of known sequences aligned in an orderly fashion on a solid surface to which labeled 
samples are hybridized [105]. In general, DNA microarray platforms are generated by 
cDNAs or short synthetic oligonucleotides (25-nucleotide-long for Affymetrix gene 
chip) onto membranes or glass slides. Before hybridization onto the array chips, the 
cDNA of interest is labeled with a fluorescent or radioactive dye (with biotin for 
Affymetrix oligonucleotide GeneChips). After hybridization, mRNA expression levels 
are measured by means of quantitative detection of fluorescent dye (by the comparison 
of samples hybridized on different chips for Affymetrix oligonucleotide GeneChips). 
The signal intensity for each spot is assumed to be proportional to the amount of each 
specific mRNA in the original sample. For that reason, the intensity difference between 
different samples can be used as the measurement of differential gene expression [106]. 
Figure 3 illustrates detailed comparison of two different microarray methods [107].  
Regardless of their ubiquity and tremendous usefulness, microarrays have certain 
limitations. First, no information can be obtained from microarray studies regarding the 
importance of translational regulation and the role of post-translational modification 
(PTMs) [108]. Second, it has been proven that the correlation between expression 
levels of mRNA and those of protein is not always perfect [109-110]. Therefore, it is 
not always accurate to conclude that changes in gene expression are direct evidence of 
consequent changes in protein expression. 
Recently, a new method called RNA sequencing (RNA-seq) has been developed 
for both mapping and quantifying transcriptomes [111-112]. In this method, cDNAs 
generated from the RNA of interest are directly sequenced using next-generation 
sequencing technologies. Briefly, a library of cDNA fragments with adaptors attached 
to one or both ends is made from a population of RNA, and then each molecule is 
sequenced in a high-throughput manner. There are major advantages of this method 
over microarray-based methods. First, RNA-seq can be used to detect transcripts that 
correspond to non-existing genomic sequence. Second, RNA-seq has better sensitivity 
and larger dynamic range. An increasing number of studies have demonstrated the 
potential for this method [113].  
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Figure 3. Comparison of two different cDNA microarray experiments 
For glass slide experiments, cDNA is prepared from two samples. After in vitro transcription (IVT), the 
two labeled cRNA samples are mixed and hybridized on a glass slide array. This is then scanned with a 
laser, followed by computer analysis of the intensity image. In Affymetrix arrays, the cDNA is used in an 
IVT reaction to generate biotinylated cRNA. After fragmentation, this cRNA is hybridized to 
microarrays, washed and stained with PE-conjugated streptavidin, and subsequently scanned on a laser 
scanner. The different abundance of a specific transcript between two samples can be obtained by 
comparing the signal from one sample to the other. 
 
1.3.2 Proteomics 
Transcriptomics employs DNA microarray technologies to investigate gene 
expression by measuring transcriptional regulation of genes via their mRNA levels. 
However, it is the proteins that act as the cellular building blocks that directly assert the 
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potential function of genes, such as enzymatic catalysis, molecular signaling, and 
physical interactions [97].  
The term proteome originally emerged to depict “the set of PROTeins encoded by 
the genOME” in 1996 [114]. The study of the proteome, proteomics, differs from 
protein analysis in that it is the characterization of the complete repertoire of individual 
protein species that comprise the proteome rather than focusing on a single protein. 
Proteomics aims to identify not only all the proteins in any given cells, but also the set 
of all protein isoforms and modifications, the interactions between them, the structural 
description of proteins and their higher-order complexes, and for that matter almost 
everything post-genomic [115].  
However, the analysis of a full proteome poses inevitable challenges due to the 
limitation and variability of sample material, sample degradation, vast dynamic range 
and a plethora of post-translational modifications (PTMs). For instance, the number of 
proteins exceeds by far the number of genes in the corresponding genome due to the 
fact that a particular gene can generate multiple distinct proteins as a result of 
alternative splicing of primary transcripts, the presence of sequence polymorphisms, 
PTMs, and other protein-processing mechanisms. Moreover, the proteome covers a 
concentration range that surpasses the dynamic range of any single analytical method or 
instrument. For example, the concentration range of serum proteins has been estimated 
to exceed 10 orders of magnitude [116]. To overcome these significant challenges in 
proteomics, new analytical strategies have been developed in which mass spectrometry 
(MS) is the central element with increased performance and versatility of the 
instrumentation. 
 
1.3.3 Mass spectrometry 
Mass spectrometry (MS)-based proteomics is a discipline made possible by the 
availability of gene and genome sequence databases and technical and conceptual 
advances in many areas, most notably the discovery and development of protein 
ionization methods, as recognized by the 2002 Nobel prize in chemistry. By the mid 
1990s MS had become a fundamental analytical technique for proteomics research. 
Since then, driven by the need to identify, characterize, and quantify proteins at ever 
increasing sensitivity and in ever more complex samples, a wide range of new MS–
based analytical platforms and experimental strategies have emerged [117].  
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Fundamentally, a mass spectrometer measures the mass-to-charge ratio (m/z) of 
gas-phase ions. By definition, it consists of three essential parts; ion source, mass 
analyzer and detector (Figure 4). An ion source converts analytes into gas-phase, a 
mass analyzer separates ionized analytes on the basis of m/z ratio, and a detector 
records the number of ions at each m/z value [118].  
 
 
 
Figure 4. Schematic presentation of a mass spectrometer 
A mass spectrometer has three essential parts, ion source, mass analyzer and detector. The ion source 
produces ions from the sample, the mass analyzer resolves ions based on their mass/charge (m/z) ratio, 
and the detector detects the ions resolved by the mass analyzer. 
 
1.3.3.1 Ionization techniques 
Proteins and peptides are polar, nonvolatile, and thermo-unstable molecules. To 
transfer those species into the gas phase without extensive degradation, a soft ionization 
technique is required. As an ion source, two ionization techniques, matrix assisted laser 
desorption/ionization (MALDI) and electrospray ionization (ESI), are generally utilized 
to volatize and ionize the proteins or peptides [119-120]. MALDI sublimates and 
ionizes the analytes out of a dry, crystalline matrix via a laser pulse, conversely ESI 
ionizes the analytes out of a solution and is typically coupled to liquid chromatography 
(LC) [121] (Figure 5).  
Preference of these two ion sources depends on the complexity of samples; 
MALDI is used for relatively simple peptide mixtures and ESI coupled to LC for 
complex samples. 
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Figure 5. Schematic picture of two kinds of ion sources, matrix assisted laser 
desorption/ionization (MALDI-left) and electrospray ionization (ESI-right) 
MALDI: After the matrix and the analyte (e.g. peptides) are mixed and co-crystallized on a metal plate, 
the laser is fired at the crystals. The matrix absorbs photons from the laser beam, and then excess energy 
is transferred to the analyte, which is ejected from the plate into the gas phase.  ESI: The analyte is mixed 
with a solvent and introduced into a capillary. A very high voltage is applied to this capillary, which 
charges the molecules in the solvent. The charged molecules pass from the capillary into the mass 
analyzer, whereas the solvent is pumped away by the vacuum system.   
 
 
1.3.3.2 Mass analyzers 
The mass analyzer is the essence of MS technology. Four types of mass 
analyzers, time-of-flight (TOF), quadrupole (Q), ion trap (IT) and Fourier transform ion 
cyclotron resonance (FTICR) are regularly employed for proteomics research. Today in 
research, it is fundamental to combine mass analyzers. Figure 6 illustrates common MS 
instruments.  
Fundamentally, a mass analyzer separates ions based on the mass-to-charge (m/z) 
ratios: TOF uses flight time, Q uses m/z stability, IT and FTICR use m/z resonance 
frequency [97]. Each mass analyzer has unique properties, such as analysis speed, 
dynamic range, ion transmission, mass range, resolution and sensitivity. In recent years, 
hybrid instruments, in which two or more mass analyzers are put together in tandem, 
have been designed to combine the capabilities of different mass analyzers to do more 
complicated protein analysis. Table 3 summarizes comparative features of the 
instruments currently most commonly used in proteomics. 
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Figure 6. MS instrumental configurations with different mass analyzers 
(A) Reflector time-of-flight (TOF): it accelerates ions by high kinetic energy, and it separates along a 
flight tube as a result of their different velocities. (B) TOF-TOF: it incorporates a collision cell between 
two TOF sections. In the first TOF section ions of one mass-to-charge (m/z) ratio are selected, fragmented 
in the collision cell, and the masses of the fragments are separated in the second TOF section. (C) 
Quadrupole: it selects ions by time-varying electric fields between four rods, which permit a stable 
trajectory only for ions of a particular desired m/z. Again, ions of a particular m/z are selected in a first 
section (Q1), fragmented in a collision cell (q2), and the fragments separated in Q3. (D) Quadrupole TOF: 
it combines the front part of a triple quadruple instrument with a reflector TOF section for measuring the 
mass of the ions. (E) Ion trap: it captures the ions as in the case of the linear ion trap, fragments ions of a 
particular m/z, and then scans out the fragments to generate the tandem mass spectrum. (F) Fourier 
transform ion cyclotron resonance: it traps the ions with the help of strong magnetic fields.  
 
 
Table 3. Comparison of commonly used mass spectrometers for proteomics 
Instrument Mass accuracy 
(ppm) 
Sensitivity m/z range MS/MS 
capability 
Ion source 
TOF 10-20 Femtomole NUL* n/a MALDI 
TOF-TOF 10-20 Femtomole NUL* MS/MS MALDI 
Q-q-TOF 10-20 Femtomole NUL* MS/MS MALDI/ESI 
Q-q-Q 100-1000 Attomole to 
Femtomole 
10-4000 MS/MS ESI 
QIT a  100-1000 Picomole 50-2000; 
200-4000 
MSn ** ESI 
Q-q-LIT b 100-500 Femtomole 5-2800 MSn ** ESI 
FTICR <2 Femtomole 50-2000; 
200-4000 
MSn ** MALDI/ESI 
* No upper limit, ** n>2, up to 13, a quadrupole ion trap, b linear ion trap 
(Modified from Han et al., 2008) 
 
The Q-q-TOF instruments demonstrate high resolution and mass accuracy in MS 
and MS/MS mode. In the MS mode, the quadrupole acts as an ion guide to the TOF 
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analyzer where the mass analysis takes place. In the MS/MS mode, on the contrary, the 
precursor ions, which are typically a multiple charged ion in ESI, are picked up in the 
first quadrupole and go into fragmentation through collision-induced dissociation (CID) 
in the second quadrupole. The product ions are analyzed in the TOF analyzer [117].  
The IT analyzers trap ions, and ions can therefore be accumulated and stored over 
time. The linear ion trap (LIT) analyzers have been replacing Q trapping devices 
because they cover a wider dynamic range and have better overall sensitivity. 
Characteristically, LIT instruments have an optional slow scanning function to increase 
resolution, and have multiple-stage sequential MS/MS capabilities, in which fragment 
ions are repeatedly isolated and further fragmented. This approach has proved to be 
very useful for the analysis of posttranslational modifications such as phosphorylation 
[122].  
 
1.3.4 Sample separation techniques for MS 
Protein MS highly depends on sample separation technologies that are needed to 
simplify complex biological samples prior to MS analysis. It should be emphasized that 
sample separation is the key to success for identification of proteins. For instance, low-
abundance species cannot be detected without appropriate sample separation, otherwise 
they will be overshadowed by higher abundance signals [97].  
There are two major approaches to separate proteins prior to MS analysis, gel-
based and gel-free separation methods. Traditionally gel-based methods have been used 
in analysis with MALDI instruments. In this method the protein band can be excised, 
digested, and off-line sampled with MALDI source [123]. High-pressure liquid 
chromatography (HPLC) is the most common gel-free method, and is usually directly 
coupled to instruments with an ESI source. In this method protein samples can be 
digested, and on-line sampled with ESI source.  
 
1.3.4.1 Two-dimensional gel electrophoresis (2-DE) 
In 1975, the basic technology for two-dimensional gel electrophoresis (2-DE) was 
illustrated by O'Farrell [124]. Since then, 2-DE has become a powerful and commonly 
used methodology to study proteomic expression followed by mass spectrometry (MS) 
for protein identification [125]. 2-DE is based on the separation of proteins in two 
dimensions. In the first dimension, proteins are separated according to their charge 
(isoelectric point, pI: the pH at which a protein carries no net electrical charge) using a 
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technique called isoelectric focusing (IEF). In the second dimension, proteins are 
separated according to their size (molecular weight) using sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) [126]. Figure 7 illustrates the general 
principle of 2-DE [108].  
 
 
 
Figure 7. General principle of 2-DE 
Proteins solubilized in buffer, typically containing high concentration of urea and detergent, are applied 
to an immobilized pH gradient strip for IEF (1st dimension). IEF separates proteins by their isoelectric 
points (pIs). SDS-PAGE (2nd dimension) separates proteins by their molecular weights.  
 
 
A major advantage of separation of proteins by 2-DE is its ability to visualize 
proteins that have undergone post translational modifications (PTM) or mutation. 
Those proteins appear as spot trains in the horizontal and/or vertical axis of the gel 
(e.g., phosphorylation, glycosylation and limited proteolysis or point mutations). 
Another advantage is that 2-DE can separate a high amount of proteins due to the 
commercial availability of a whole range of different pH strips for first dimension 
separation [108]. Therefore, 2-DE can simultaneously separate about 2,000 proteins in 
a single gel depending on the chosen pH gradient and gel size [125]. In contrast, one of 
major drawbacks of 2-DE is the spot visualization of low abundant proteins since 
proteins have a wide dynamic range in abundance [127]. Another major drawback of 2-
DE is the resolution of membrane and large hydrophobic proteins since most of them 
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are not soluble in aqueous solution and thus do not enter the pH strips during the first 
dimension [128-129].  
 
1.3.4.2 High pressure liquid chromatography (HPLC) 
High pressure liquid chromatography (HPLC) separates analytes based on their 
idiosyncratic polarities and interactions with the column's stationary phase. In MS-
based proteomics, the following types of HPLC chromatographic materials are most 
commonly used: reverse phase (RP), ion exchange (IEX), hydrophilic-interaction 
chromatography (HILIC), affinity, and hybrid materials [97].  
The reverse phase liquid chromatography (RPLC) is as indispensable to gel-free 
LC/MS as 2-DE is to gel-based proteomics [130]. RPLC separates peptides based on 
their hydrophobicity. The significant advantages of RPLC are that the buffers used are 
compatible with ESI and that RPLC desalts the sample [131-132]. The disadvantage is 
that it seldom provides enough resolution. However, by decreasing the diameter of the 
packing materials or by using narrow-bore, long columns under ultra-high pressure 
conditions, this issue has been overcome and separation performance has been 
improved dramatically [133]. 
Multidimensional separation, which combines several separation techniques 
coupled to improve the resolving power, is employed to tackle high sample complexity. 
In reality, analytical samples like tissue lysate or bio-fluid contain thousands of proteins 
that can range upward of five orders of magnitude in their abundance [127]. Moreover, 
the complexity of protein samples becomes even higher after being digested by trypsin, 
which, in turn, yields multiple peptide products [134]. It is essential for 
multidimensional separation to consider the orthogonality of the individual separation 
methods in which each dimension uses different properties of molecules as a basis for 
separation [135]. 
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1.3.5 Analytical techniques for protein identification 
Typically, two different analytical techniques are used to identify proteins in MS 
analysis. One is Peptide Mass Fingerprinting (PMF) in which the experimental 
spectrum obtained by MALDI (Figure 8) is compared with theoretical ones. These are 
computed from protein sequences stored in databases and in silico digested using the 
same cleavage specificity of the protease employed in the experiment [136]. The 
PMF method is suitable for identification of isolated proteins. Complicated mixtures 
of proteins typically require the use of tandem mass spectrometry (MS/MS) based 
protein identification to achieve sufficient specificity of identification [137].  
 
 
 
Figure 8. A typical MS spectrum obtained by MALDI 
After a MALDI spectrum has been de-isotoped, a list of peaks, each of which represents a peptide, is 
created. A list of peaks is submitted to the database for analysis using a library of protein sequences. 
 
MS/MS is another technique for protein identification by sequencing peptides 
(Figure 9). To fragment peptides, the technique called collision-induced dissociation 
(CID) [138] has been widely used. In general with this method, the precursor ions are 
picked up first, and go through peptide backbone fragmentation of C-N bonds resulting 
in a series of b-fragment and y-fragment ions [118]. However, the usage of CID is not 
suitable for sequencing peptides containing more than fifteen amino acids and intact 
proteins.  
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Figure 9. A typical MS/MS spectrum obtained by ESI 
The MS/MS spectrum of mouse “EH-domain containing 4” peptide "AMQEQLENYDFTK". The 
sequenced peptide is blasted in the database to identify the protein.  
 
 
1.3.6 Relative quantitative proteomics 
In the past decade, the trend of proteomics research has shifted from simple 
identifications to complex quantitation of proteins for the understanding of cellular 
activities, disease developments and physiological responses to therapeutic 
interventions and environmental perturbations. Relative quantitative proteomics allows 
for simultaneous identification of hundreds of proteins and reveals differences in 
protein abundance between distinct samples [139] With the aim of investigating 
differential protein expression in complex biological samples, there are two approaches 
employed in MS-based proteomics; a gel-based method for intact proteins and a non 
gel-based method for enzymatically digested peptides. 
 
1.3.6.1 Differential gel electrophoresis (DIGE) 
Optical detection of proteins with a fluorescent label has an excellent dynamic 
range, and 2-DE is well-suited to separate and analyze proteins and their isoforms. 
Combining these two methods, Differential Gel Electrophoresis (DIGE) was invented 
for quantitative analysis of intact proteins [140]. DIGE is a technique allowing 
quantitative proteomics of two or more samples by optical fluorescence detection of 
differentially labeled proteins that are electrophoretically separated on the same gel 
[141]. This methodology involves pre-labeling several samples with spectrally distinct 
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fluorescent dyes (e.g. Cy2, Cy3, and Cy5) coupled to primary amines such as the N-
terminus and lysine residues, followed by sample multiplexing and co-resolution on the 
same 2-DE gel to eliminate gel to gel variations [142]. Moreover, multi-variant analysis 
can be inter-compared with a relatively small number of coordinated DIGE gels using 
internal standards and experimental repetition. 
DIGE is an extremely sensitive method for detection of proteins. It can detect less 
than 1 fmol of protein, and allows linear detection of over more than 104 fold protein 
abundance range [143-144]. Conversely, this methodology has some limitations 
including low-throughput and labor-intensive operation with high dependence on the 
expertise of the operator. In addition, 2-DE does not perform well for hydrophobic and 
very acidic or basic proteins [145]. 
 
1.3.6.2 Stable isotope-labeling methods  
Two general approaches are utilized to incorporate stable isotopes into 
proteins/peptides for relative quantitation, metabolic labeling and chemical 
derivatization. For metabolic labeling, cells are cultured in isotopically defined and 
distinct medium containing unique isotope-labeled amino acids (heavy Arg, Lys, Leu 
and Ile). The relative-abundance ratio of peptides with identical primary sequence from 
mixed cell lysates is measured by comparing heavy/light peptide pairs by MS [97, 146]. 
One of the commonly used approaches is stable-isotope labeling by amino acids in cell 
culture (SILAC).  
In an experiment employing SILAC, the labeled SILAC amino acids, for instance 
13C labeled L-lysine, are supplied to cells in culture instead of the natural amino acids, 
and the SILAC amino acids are incorporated into all newly synthesized proteins. After 
at least five cell divisions, replacement of amino acids will be completed [147]. In view 
of the fact that there is hardly any chemical difference between the labeled amino acid 
and the natural amino acid isotopes, the two cell populations should behave exactly the 
same in the presence of normal or labeled amino acid. In general, much less sample 
preparation for quantitative studies is required for metabolic labeling experiments, 
although tissue samples or body fluids cannot be used [145]. 
Chemical derivatization strategies, including isotope-coded affinity tags (ICAT) 
[148] and isobaric tags for relative and absolute quantification (iTRAQ) [149] allow 
measurement of changes in expression levels between two proteomes in a single MS-
based experiment. Concisely, for the relative quantitation of peptides from proteolytic 
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digestion of complex protein mixtures, an isotopically unique functional group is added 
chemically to a peptide to distinguish separate samples by their unique mass [145].  
In the ICAT method, proteins from two different biological samples are labeled 
with a biotin-containing heavy (typically 2H or 13C) or light (native) version of a reagent 
that selectively couples to the side chain of a reduced cysteine residues [148]. 
Subsequently, the labeled proteins are combined and proteolytically digested into 
peptides, and affinity purification using streptavidin is applied for enrichment of 
labeled peptides. Utilizing the ratio of the signal intensities from the ‘heavy’ and ‘light’ 
forms of each peptide, the relative abundance of peptides is determined by MS analysis. 
Subsequently individual peptide ratios from the same protein are combined to produce 
abundance ratios of identified proteins in the sample [150]. A major advantage with 
ICAT is that it enhances the detection of low-abundance proteins due to the enrichment 
of the modified peptides via affinity purification of the biotin moiety. Nonetheless, 
because of selectiveness of the ICAT reagent, which only labels proteins/peptides 
containing cysteine residues, quantitation of proteins not containing a cysteine residue 
will not occur [146]. 
In the iTRAQ method, amine-specific isobaric reagents are used to label the 
primary amines of peptides for the concurrent quantitative comparison of up to eight 
different biological samples [151-152]. This method was developed to solve some of 
the limitations of ICAT. Compared to the ICAT method which produces multiple MS 
peaks per peptide, the MS spectrum of each peptide in this method does not increase in 
complexity owing to the isobaric nature of the tagging reagents. Relative peptide 
abundance measurements between the samples are made based on the relative intensity 
of each reporter ion with distinct m/z, which is released during peptide fragmentation. 
In contrast to ICAT, iTRAQ theoretically labels all peptides in a mixture. However, 
labeling after protease digestion in the iTRAQ method limits the use of reporter ions as 
internal standards since experimental variations at prior sample preparation steps are 
not accounted for [146]. Table 4 summarizes three stable isotope-labeling methods 
[153]. 
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Table 4. Comparison of three methods: SILAC, ICAT and iTRAQ 
 how to label suitable sample when to digest where to label 
SILAC metabolically cell culture after labeling depends* 
ICAT chemically anything after labeling cysteine residues 
iTRAQ chemically anything before labeling primary amine 
*One or several amino acids depends on the media used 
 
 
  advantages disadvantages 
SILAC • replacement of AA** occurring in the 
biological system  
• flexible sample preparation  
• applicable only to cell cultures 
ICAT • any biological materials can be used 
• detection of low-abundance proteins 
• relatively extreme chemical conditions 
• only labeling proteins/peptides containing 
cysteine residues  
iTRAQ • completion of the tagging reaction without 
major side reactions 
• up to eight different samples can be used 
• expensive in large-scale experiments 
• variation of sample preparation 
**Amino acids                                                                                                    (modified from Wilm, 2009) 
 
 
1.3.6.3 Label-free methods 
Label-free quantification requires only minimal modification of the sample and is 
therefore the most compatible method for quantifying the expression changes of 
proteins in large-scale proteomics studies [153]. The foundation of label-free 
approaches is the comparison of distinct regions of m/z and retention time which 
represent the same analyte across multiple analyses. This method functions based on 
the observation that signal intensity from ESI correlates with ion concentration [154] 
and that an ion with a particular m/z is detected at a particular time.  
There are some practical constraints to this method for the quantitation of protein 
abundances in several complex biological samples. One drawback is the difference in 
the peak intensities of the peptides from the same sample between runs, caused by 
experimental variation such as sample injection. The other hurdle is chromatographic 
shifts in retention time which occur as a result of multiple sample injections onto the 
same reverse-phase LC column [155]. Therefore, the thorough strategy, including 
meticulous experimental design, cutting-edge computational method, and highly 
reproducible technology, is vital in this comparative approach to normalize and correct 
experimental variances which affect MS intensity and retention time [146]. 
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2 Aim of the study 
 
The overall aim of this study was to investigate the kidney glomerulus at mRNA 
and protein level and to provide new insights into the biological and pathological 
processes of the glomerulus. To accomplish this goal, glomeruli were isolated from 
both healthy and diseased kidneys and studied by expression profiling and protein 
analyses. The specific aims were to: 
 
I:  Identify glomerular proteins from mouse kidneys using two dimensional gel 
electrophoresis and mass spectrometry. 
 
II: Characterize novel proteins in the kidney, which are highly expressed in mouse 
glomeruli. 
 
III: Perform glomerulus specific transcriptome profiling in the adriamycin-induced 
proteinuric mouse model.  
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3 Experimental procedures 
 
In this section, various methodologies employed throughout this study are briefly 
described. Detailed descriptions can be found in the “Materials & Methods” sections of 
the corresponding papers (I, II and III). 
 
Isolation of mouse kidney glomeruli (I and III) 
 
Glomeruli were isolated by the Dynabeads® perfusion method [156] using female 
C57BL/6 mice for paper I and female BALB/c mice for paper III. Figure 10 illustrates 
the procedure of isolation of glomeruli.  
 
 
Figure 10. Flow chart of mice glomeruli isolation technique 
 
Briefly, an anesthetized mouse was perfused through the left ventricle with 
HBSS containing 8x107 Dynabeads® (Invitrogen, CA). The kidneys were removed, 
minced and digested with collagenase A and DNase I for 30 min at 37 °C for RNA 
isolation (III). For extraction of the whole proteome from the glomeruli, collagenase 
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treatment was eliminated to avoid digestion of extracellular proteins (I). Minced 
kidney tissue was then sieved through a 100 µm cell strainer, and the glomeruli-
containing magnetic Dynabeads were collected with a magnetic particle concentrator. 
The glomeruli were counted and checked for purity under a light microscope. 
 
Extraction of proteins from isolated mouse glomeruli (I and II) 
 
Isolated glomeruli were suspended in water, and the suspension underwent four 
freeze-thaw cycles using liquid nitrogen to disrupt the cells. The samples were then 
freeze-dried under vacuum. Dried samples were solubilized in a buffer containing 
urea, DTT, and detergents in a shaker at 20 °C for 4 h. After centrifugation, 
supernatants were collected and protein concentrations measured with the Bradford 
assay. 
 
Two-dimensional gel electrophoresis (I) 
 
Protein extracts, 75 µg for silver-stained gels and 500 µg for the CBB-stained 
gels, were applied onto 17 cm IPG strips, and IEF was carried out with total voltage 
hours (Vh) of 51000 for the pI 4–7 strips and 35000 Vh for the pI 3–10 strips. The 
second dimension was performed on homemade 8–16% gradient SDS-PAGE gels. 
The gels were stained with silver or CBB. Molecular weights of proteins were 
determined by comparisons with positions of protein standards.  
 
Sample preparation for mass spectrometry (I) 
 
Protein spots were excised manually from both the CBB-stained and the silver-
stained gels. Gel pieces were cut into small pieces and digested with trypsin using a 
protocol previously published [157]. Peptides were extracted from gel spots with 
acetonitrile solution containing formic acid. Acetonitrile was removed, and then 
samples were desalted manually with ZipTips® (Millipore, MA). For MALDI 
analysis, desalted samples were mixed 1:1 with a matrix solution containing α-cyano-
4-hydroxycinnamic acid. For reduced matrix adduct formation in spectra, ammonium 
phosphate was added to the matrix [158]. 
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Mass spectrometry analysis of trypsin digested proteins (I) 
 
A MALDI instrument, Q-TOF Ultima (Waters, MA), was employed for peptide 
mass fingerprinting (PMF). The instrument was calibrated with a polyethylene glycol 
standard between 80–2500 m/z, and was operated in single reflector mode and with 
positive ion data. The MS software, MassLynx Version 3.4, was used to create a peak 
list, and MaxEnt3 was applied for each list before submitting into the Mascot search 
engine (http://www.matrixscience.com/).  
A LC-API instrument, Q-TOF Ultima tandem mass spectrometer was utilized 
for amino acid sequences of relevant peptide samples for the identification of 
samples, which could not be confirmed by PMF experiment. Data-dependent 
acquisition (DDA) was used at 300–1600 m/z in MS mode and 50–1600 in MS/MS 
mode with a scan rate of 1 s and automatic switching from MS to MS/MS mode on 
multiple charged ions. PLGS 2.2.3 was used to a pkl-file for protein data searches. 
 
Production of Polyclonal Antibodies (II) 
 
Antibodies were made using tagged recombinant proteins as antigens. Briefly, 
after antigens were expressed as tagged recombinant proteins (His-tag for dendrin, 
GST-tagged for ehd3) in bacteria, they were purified by affinity chromatography, 
followed by ion-exchange chromatography. Purified antigens were utilized for 
production of antibodies by immunization of NZW rabbits using standard protocols.  
 
Western Blotting (II) 
 
 Western blotting was carried out following standard procedures using polyvinyl 
difluoride (PVDF) membranes. Briefly, 10 µg of proteins were separated by SDS-
PAGE and transferred to a PVDF membrane. Then, the membrane was blocked, and 
incubated with a primary antibody. After being washed for 2 hrs, the membrane was 
incubated with horseradish peroxidase–conjugated secondary antibody. The protein of 
interest was detected by chemiluminescence.   
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Immunohistochemistry (II) 
 
Adult mouse kidney was used for immunofluorescence staining. Kidneys were 
snap-frozen, and the cryosections (10 µm) were postfixed with cold acetone, followed 
by blocking in 5% normal goat serum. The primary antibodies were incubated overnight 
at 4 °C, followed by the incubation with fluorescent secondary antibody. 
 
Induction of ADR nephropathy in mice (III) 
 
Six-week-old female BALB/c mice, weighing 16-20 g, were used. Adriamycin 
(ADR, doxorubicin hydrochloride) was diluted with isotonic saline solution (0.9% 
NaCl) to 2 mg/ml, and was injected as a single dose via the tail vain at a dosage of 10.5 
mg/kg body weight.  
 
Urine and blood analysis of ADR-induced proteinuric mice (III) 
 
Spot urine was collected from mice. To confirm proteinuria, 1 µl of urine was 
applied to an SDS-PAGE gel, and the gel was stained with PageBlue™. Total 
urinary protein concentration was quantified using Coomassie Plus. Urinary 
creatinine was quantified using the QuantiChrom™ Creatinine Assay Kit to 
calculate protein/creatinine ratio. Blood samples for blood urea nitrogen (BUN) 
measurements were collected under anesthesia by cardiac puncture. BUN was 
quantified using the QuantiChrom™ Urea Assay Kit.  
 
Histological assessment (light- and electron-microscopy) (III) 
 
For light microscopy, kidneys were fixed in 4% paraformaldehyde (PFA) at 4 °C 
for 24 h and then dehydrated in graded alcohols and embedded in paraffin. Sections (4 
µm) were stained with hematoxylin and eosin (HE). For electron microscopy, small 
kidney pieces were fixed in 0.05 M sodium cacodylate buffer with 2% PFA and 2.5% 
glutaraldehyde. 
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TUNEL staining and positive cell counting inside glomerulus (III) 
 
Terminal deoxynucleotidyl transferase dUTP Nick End Labeling (TUNEL) 
staining was performed to assess the presence of apoptotic cells. Anti-podocalyxin 
antibody was used for labeling the secondary foot processes of the podocytes. In each 
sample, 100 glomeruli were counted randomly, and glomeruli containing TUNEL 
positive cells were analyzed using Volocity software. The counting was repeated three 
times for each sample.      
 
Microarray analysis (III) 
 
Total RNA from glomeruli was extracted using RNeasy Mini kit (Qiagen, Hilden, 
Germany). Extracted RNA was labeled and hybridized on Affymetrix Mouse Genome 
430 2.0 chip. Affymetrix data were processed using the R software (version 2.9.0) and 
the Bioconductor packages. Affymetrix raw data were normalized with the gcrma 
method (R package version 2.16.0). After normalization, samples were subjected to 
hierarchical clustering (Euclidian distance, average linkage).  
To identify differentially expressed genes between samples, all probe sets with 
expression changes more than two-fold at any time point were selected. The student t-
test (two sided) was applied to examine the significance. Multiple test correction was 
done using the False Discovery Rate (FDR) method and a FDR <0.1 was used to select 
the differentially expressed genes. 
  32
4 Results and discussion 
In Paper I, we described the use of 2-DE gel electrophoresis and mass 
spectrometry analysis to generate new information about the healthy glomerular 
proteome in mouse as a basis for later studies on the glomerular proteome from 
diseased kidneys.  
After the isolation of glomeruli, the purity and number were checked under a 
light microscope. The glomeruli appeared to be highly pure and devoid of Bowman’s 
capsule. The number of glomeruli obtained from one mouse was approximately 
20,000. The amount of glomerular protein extracted from one mouse was 
approximately 100 µg. 
Total glomerular, denatured protein extracts were subjected to two different pH 
ranges of immobilized pH gradient (IPG) strips for IEF, and two different methods 
were used to stain the gels (Table 5).  
 
Table 5. Summary of three 2-DE experiments 
 
pH range of IPG 
strip 
Gel-staining 
method 
number of spots 
detected 
number of 
spots excised 
3 to 10 CBB* 342 96 
4 to 7 CBB* 625 192 
4 to 7 silver 922 480 
* Coomassie Brilliant Blue 
Each excised spot was digested with trypsin and analyzed individually first by 
MALDI-TOF MS for peptide mass fingerprinting (PMF), using a minimum of four 
matching peptides, a coverage of 12% of the protein, minimal scores and maximal 
expected values as given for approval of the identification of protein. Furthermore, 
relevant protein spot identifications were checked by amino acid sequence analysis 
using LC-MS/MS. Eventually, 414 protein spots, representing 232 different proteins, 
were identified. 72 out of 232 proteins were identified by silver staining.  
Most of the identified proteins are ubiquitous, housekeeping proteins whereas 
several are cytoskeletal structural proteins highly expressed in podocytes (actin, F-
actin, vimentin, α-tubulin, β-tubulin), as reported previously [159]. Even though 
previous 2-DE studies of the kidney glomeruli have not been able to identify any 
proteins expressed specifically in the kidney podocyte slit diaphragm, we did identify 
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α-actinin-4 and nephrin, which are known to play important roles in the glomerular 
filtration barrier and its diseases. 
Surprisingly, only 53 out of the 232 identified proteins had been detected in 
other glomerular proteome studies [159-160]. This result could be due to many 
factors, including the use of several identification methods and the quality of tissue 
preparations. Altogether, our result demonstrates the value of repeated proteome 
analyses using different methodologies.  
Comparison of proteome analyses of endothelial and mesangial cells to that of 
ours revealed that these proteome studies detect many of the housekeeping proteins 
shared by similar tissues [160-161]. In addition, comparison of the results of these 
direct proteome studies with those of separate transcriptome analyses exposed that an 
independent glomerular-specific cDNA library analysis [56] could not identify all of 
these proteins. This shows that multiple approaches are indispensable to complement 
each other in final interpretations of functional relationships.  
Miyamoto et al. analyzed the human glomerular proteome using a different 
approach from ours [162] . They separated proteins using 1-D (SDS-PAGE) and 2-D 
(solution-phase IEF in combination with SDS-PAGE) prefractionation prior to the 
shotgun analysis with LC−MS/MS. As a result, they identified around 3,000 unique 
proteins. This fact proves that prefrationation of the sample before applying to MS 
analyses is vital. Due to drawbacks of 2-DE, a limited dynamic range for detection, and 
a poor resolution of membrane and large hydrophobic proteins, more effective and 
sensitive methods have emerged and are now replacing 2-DE. Multidimensional liquid 
chromatography (MDLC) is one of these. An HPLC based MDLC platform can reduce 
the sample complexity prior to the MS analysis, and can therefore maximize the 
chances that the MS will detect peptides present in tryptic digest of a proteome [163]. 
 
In Paper II, we characterized five novel transcripts/proteins that were identified 
among more than 300 glomerulus-upregulated transcripts in a large-scale sequencing 
and microarray profiling analysis of the glomerular transcriptome [56]. The 
transcripts/proteins, ehd3, dendrin, sh2d4a, plekhh2, and 2310066E14Rik were 
characterized with respect to their expression profiles in detail. RT-PCR and Northern 
blotting experiments demonstrate the presence of four transcripts, except plekhh2, in 
kidney, and the size of each transcript was in agreement with the predicted cDNA size 
described in the NCBI database. In addition, Western blotting experiments revealed the 
presence of five proteins in glomerular lysate but not in the rest of kidney, and the size 
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of each protein was in agreement with its predicted protein size. The glomerulus 
specificity of three mRNAs, dendrin, ehd3 and2310066E14Rik, was verified using in 
situ hybridization, and the localization of five proteins was revealed to be specific to the 
glomerulus based on immunofluorescence staining. Dendrin, Sh2d4a, and Plekhh2 
proteins were localized to the slit diaphragm and the foot process, 2310066E14Rik 
protein was localized to the podocyte major processes and cell body, and the Ehd3 
protein was localized to glomerular endothelial cells (GECs). 
It is known that several critical glomerular proteins, such as nephrin, podocin and 
NEPH1 have very restricted expression patterns, and these crucial proteins are 
expressed exclusively by podocytes in the kidney glomerulus [13, 15, 164]. Therefore, 
the limited expression pattern of the proteins discovered in this study advocates that 
they may have a highly specific role in the glomerulus.  
We hypothesize that dendrin may act as a linker molecule between the slit 
diaphragm and the actin cytoskeleton based on our finding that dendrin is located at the 
cytoplasmic face of the slit diaphragm. This hypothesis is supported by recent data  
showing that dendrin interacts in vivo with two cytoskeletal components, α-actinin and 
membrane-associated guanylate kinase inverted (MAGI) [165]. We found that ehd3 
was expressed specifically in GECs, and to our knowledge Ehd3 is, thus, the first 
protein shown to be expressed only in GECs and not by other endothelial cells. This 
discovery is intriguing because the use of the ehd3 promoter may enable the generation 
of a GEC-specific Cre mouse line, and such a mouse line could be a vital tool for future 
research. We discovered that both cytosolic proteins, Sh2d4a and Plekhh2, are 
expressed only in podocytes, and at the subcellular level, we localized these proteins 
specifically to the foot processes. Our hypothesis is that Sh2d4a protein may be 
involved in slit diaphragm signaling and that the Plekhh2 protein may be involved in 
connecting the slit diaphragm to the actin cytoskeleton. 
 
In the work described in paper III, we compared the glomerular transcriptome in 
normal and disease states, as well as its changes during progression or recovery of 
glomerular disease utilizing the adriamycin (ADR)-induced proteinuric mouse model. 
This model is highly reproducible and allows the precise timing of the onset of 
proteinuria and the change of morphology in glomerulus, therefore, is excellent to study 
expression profiles during disease progression. 
All animals injected with a single dose of ADR developed nephrotic syndrome 
characterized by body weight loss, massive proteinuria, and elevated BUN. Overt 
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proteinuria was observed four days after ADR injection, and the leakage of serum 
albumin reached its maximum at seven days.  Electrophoresis of urinary proteins using 
SDS-PAGE revealed that proteinuria in ADR-injected mice consisted mainly of 
albumin with a molecular weight of about 70 kDa.  
Apparent morphological changes in ADR-injected mice kidney were observed at 
day seven in electron microscopy as segmental podocyte foot process effacement was 
detected. Light microcopy revealed first pathological changes at day 14 as resorption 
droplets and intraluminal casts were detected in the tubular compartment. TUNEL 
staining revealed an increase in apoptotic positive cells in glomeruli of ADR-injected 
mice, and the number of apoptotic positive cells gradually increased after ADR 
injection, reaching a maximum at 14 days after ADR injection.  
Affymetrix microarray experiments were performed using mRNA from isolated 
kidney glomeruli at four time points (0, 4, 7 and 14 days). Four days after ADR 
injection a total of 698 genes were differentially expressed in the acute injury phase. 
Nine p53 target genes were found to be up-regulated probably due to DNA damage 
caused by ADR.  Five inflammatory response genes were found to be up-regulated and 
one gene, Socs3, was found to be down-regulated due to ADR toxicity. Two apoptosis 
related genes, Serpina3g and Tnfrsf12a, were found to be up-regulated. Three AP-1 
(active protein-1) genes, belonging to the family of dimeric transcription factors 
binding to the AP-1 binding site of DNA, Atf3, Fos and Fosb, were all found to be 
down-regulated.  
 Since ADR is known to cause oxidative DNA damage [166], it was not 
surprising to observe a major increase in the levels of transcripts related with the p53 
protein pathway in the acute injury stage at 4 days after ADR injection [167-168]. 
Although the expression of p53 itself did not significantly change, the expression of 
nine p53 target genes was changed at 4 days after ADR injection. The change of these 
genes expressions and the number of apoptotic cells inside glomeruli suggest that DNA 
damage due to injection of ADR has occurred and led to apoptosis of glomerular cells. 
However, since the number of apoptotic cells inside the glomeruli is still relatively 
small four days after ADR injection, and the proteinuria has not reached maximum, the 
podocytes and the glomerular filter have probably not yet become extensively 
damaged. 
275 genes were differentially expressed at the seven days stage. Several genes 
indicating glomerular injury were differentially expressed seven days after ADR 
injection. Three genes related to human kidney diseases and proteinuria, Ankrd1[169], 
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Cyr61[170] and Serpine1 [171], were found to be up-regulated. Two DNA damage 
response genes were found to be up-regulated. Four podocyte enriched/specific genes 
were found to be down-regulated, suggesting podocyte injury caused by ADR [172].  
At 7 days after ADR injection, the ratio of urine protein/creatinine had reached 
its maximum and there was extensive effacement of podocyte foot processes. At that 
time one could observe a marked change in the expression of several podocyte 
specific genes. As could have been expected, several genes expressed specifically in 
podocytes were down-regulated at this stage. Ddn (dendrin) is one of them, and is a 
specialized cell junction component present at the slit diagram (SD), where 
interdigitating foot processes of podocytes are connected [173]. As dendrin is known 
to bind directly to nephrin and CD2AP in the slit diaphragm [174], we examined the 
expression levels of those genes. Dendrin is relocated from the slit diaphragm to the 
nucleus of injured podocytes in experimental glomerulonephritis [174], but we could 
not detect the protein in the nuclei of podocytes in ADR-induced nephropathy. 
Considering the present data that show changes in the expression of podocyte specific 
genes at seven days after ADR injection, it is clear that ADR causes extensive 
podocyte injury, which leads to end stage renal failure.  
A total of 600 genes were differentially expressed 14 days after ADR injection, at 
a stage when slight recovery of glomerular injury and the proteinuria had initiated. Two 
genes, Fgfbp1 and Acvrl1, were found to be up-regulated only at this time point. The 
majority of genes up-regulated at this point were found to be up-regulated from day 4 
or day 7 after ADR injection.  
At 14 days after ADR injection, overt proteinuria was still present and the 
number of apoptotic cells in glomeruli had further increased. Also, morphological 
changes were still observed in the kidney cortex by light microscopy. The proteinuria 
caused by ADR-induction is not transient and reversible like it is in LPS-induced 
proteinuria mice model [88].  
Several genes were significantly expressed at all three time points, days 4, 7 and 
14. Cdkn1a was one of those genes, which interestingly is known to play dual roles. 
Cdkn1a protein has prosurvival or proapoptotic function depending on its relative 
protein levels, subcellular localization and protein–protein interactions [175-178]. To 
verify which role Cdkn1a plays in the ADR-induced nephropathy model, we examined 
the expression of genes that are directly or indirectly linked with Cdkn1a. 57 genes 
were categorized into two groups; 20 genes to be positively correlated to and 37 genes 
to be negatively correlated to Cdkn1a expression profiles. Among them, five p53-
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related genes were found to be positively correlated to Cdkn1a expression profile 
indicating that p53 was induced by ADR injection followed by DNA damage. Two 
anti-apoptotic genes were also positively correlated with Cdkn1a expression profile 
indicating these genes restrained the number of apoptotic cells in glomeruli. On the 
other hand, eight podocyte specific genes were found to correlate negatively with the 
Cdkn1a expression profile indicating that the podocyte was the direct target of ADR-
induced DNA damage.  
We conclude that ADR causes DNA damage inside glomeruli and it may lead 
to podocyte injury. It is not exactly clear which part of glomeruli is primarily affected 
by ADR, or which pathways are involved to induce overt proteinuria. Further 
investigations are needed to reveal which genes and pathways play important roles in 
the development of proteinuria in the ADR-induced proteinuric model.   
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5 Conclusions and future perspectives 
Identification of proteins in mouse glomeruli using 2-DE gel electrophoresis 
and mass spectrometry with two different staining methods provided new knowledge 
about proteomes in glomeruli, but the amount of identified proteins was highly 
limited. Characterization of five novel genes, specifically expressed in glomeruli, 
rendered new information on novel proteins. They will be interesting to study further 
for function in mouse models and expression in glomerular diseases. Comparison of the 
glomerular transcriptome in normal and disease states, as well as its changes during 
progression or recovery of glomerular disease utilizing the ADR-induced proteinuric 
model in mouse gave us additional intuition toward understanding the pathogenesis of 
proteinuria. It is apparent that extensive transcriptome analysis of isolated glomeruli 
will yield immense new information on various glomerular diseases. Such analyses 
may have diagnostic value in the future.  
Our knowledge about the gene and protein expression complexity in the 
glomerulus has been accumulating steadily over the years. At the same time, new 
technologies are arising to explore new information concerning the structure and 
development of the renal filter and its cellular and extracellular components. 
Furthermore, transcriptome and proteome analysis of human diseases affecting 
glomerular function, and of animal models of these diseases, will lead to the 
identification of critical developmental and maintenance processes, and unique and 
common pathogenic pathways involved in glomerular disease. 
In conclusion, it is crucial to combine large-scale expression profiling platforms 
(RNA-seq), quantitative proteomics using mass spectrometry, transgenic mouse lines, 
and other in vivo gene delivery methods. That will further expand our understanding of 
the physiology and pathphysiology of the glomerular filtration barrier, and reveal novel 
target molecules for the therapy of kidney diseases. 
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